MY108089A - N-substituted heterocyclic derivatives,their preparation and the pharmaceutical composition in which they are present. - Google Patents

N-substituted heterocyclic derivatives,their preparation and the pharmaceutical composition in which they are present.

Info

Publication number
MY108089A
MY108089A MYPI92001566A MYPI19921566A MY108089A MY 108089 A MY108089 A MY 108089A MY PI92001566 A MYPI92001566 A MY PI92001566A MY PI19921566 A MYPI19921566 A MY PI19921566A MY 108089 A MY108089 A MY 108089A
Authority
MY
Malaysia
Prior art keywords
cyano
alkyl
unsubstituted
substituted
cycloalkyl
Prior art date
Application number
MYPI92001566A
Inventor
Muneaux Yvette
Perreaut Pierre
Muneaux Claude
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of MY108089A publication Critical patent/MY108089A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/70—One oxygen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/84—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

THE INVENTION RELATES TO N-SUBSTITUTED HETEROCYCLIC DERIVATIVES AND ITS SALTS. THESE DERIVATIVE HAVE THE FORMULA (FORMULA 1) IN WHICH: -R1 AND R2 ARE SIMILAR OR DIFFERENT AND ARE EACH INDEPENDENTLY HYDROGEN OR A GROUP SELECTED FROM A C1-C6 ALKYL; A C1-C4 ALKOXY, AN AMINO, AN AMINO-METHYL, A CARBOXYL, AN ALKOXYCARBONYL IN WHICH THE ALKOXY IS C1-C4, A CYANO, A TETRAZOLYL, A METHYLTETRAZOLYL, A METHYLSULFONYLAMINO, A TRIFLUOROMETHYLSULFO-NYLAMINO, A TRI-FLUOROMETHYSULFONYLAMINOMETHYL, AN N-CYANO ACETAMIDE, AN N-HYDROXYACETAMIDE, AN N-(4-CARBOXY-1,3-THIAZOL-2-YL)ACETAMIDE, A UREIDO, A 2-CYANO-GUANIDINOCARBONYL, A 2-CYANO-GUANIDINOMETHYL, AN IMIDAZOL-1-YL CARBONYL AND A 3-CYANO-2-METHYLISOTHIOUREIDOMETHYL, WITH THE PROVISO THAT AT LEAST ONE OF THE SUBSTITUENTS R1 AND R2 IS OTHER THAN HYDROGEN; -R3 IS A HYDROGEN, A C1-C6 ALKYL WHICH IS UNSUBSTITUTED OR SUBSTITUTED BY ONE OR MORE HALOGEN ATOMS, A C2-C6 ALKENYL, A C3-C7 CYCLOALKYL, A PHENYL, A PHENYLALKYL IN WHICH THE ALKYL IS C1-C3 OR A PHENYLALKENYL IN WHICH THE ALKENYL IS C1-C3, SAID PHENYL GROUPS BEING UNSUBSTITUTED OR MONOSUBSTITUTED OR POLYSUBSTITUTED BY A HALOGEN ATOM, A C1-C4 ALKYL, A C1-C4 HALOGENOALKYL, A C1-C4 POLYHALOGENOALKYL, A HYDROXYL OR A C1-C4 ALKOXY; -R4 IS A C1-C6 ALKYL WHICH IS UNSUBSTITUTED OR SUBSTITUTED BY ONE OF MORE HALOGEN ATOMS; AND -R5 IS A CYCLOALKYL OR A CYCLOALKYMETHYL, SAID CYCLOALKYL BEING C3-C7, WHICH IS UNSUBSTITUTED OR SUBSTITUTED BY ONE OR MORE HALOGEN ATOMS; -OR R4 AND R5 EACH A CYCLOPROYL; -X IS AN OXYGEN ATOM OR SULFUR ATOM; AND -Z AND T ARE ZERO OR ONE IS ZERO AND THE OTHER IS ONE. APPLICATION: ANGIOTENSION II ANTAGONISTS.
MYPI92001566A 1991-09-10 1992-09-04 N-substituted heterocyclic derivatives,their preparation and the pharmaceutical composition in which they are present. MY108089A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9111161A FR2681067B1 (en) 1991-09-10 1991-09-10 N-SUBSTITUTED HETEROCYCLIC DERIVATIVES, THEIR PREPARATION, THE PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME.

Publications (1)

Publication Number Publication Date
MY108089A true MY108089A (en) 1996-08-15

Family

ID=9416798

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI92001566A MY108089A (en) 1991-09-10 1992-09-04 N-substituted heterocyclic derivatives,their preparation and the pharmaceutical composition in which they are present.

Country Status (19)

Country Link
EP (1) EP0532410A1 (en)
JP (1) JPH05213894A (en)
KR (1) KR930006008A (en)
AU (1) AU661017B2 (en)
CA (1) CA2077967A1 (en)
CZ (1) CZ275992A3 (en)
FR (1) FR2681067B1 (en)
HU (1) HUT63616A (en)
IL (1) IL103116A (en)
LT (1) LT3148B (en)
LV (1) LV10255B (en)
MX (1) MX9205155A (en)
MY (1) MY108089A (en)
NO (1) NO180678C (en)
NZ (1) NZ244258A (en)
PL (1) PL171524B1 (en)
RU (1) RU2107062C1 (en)
TW (1) TW218871B (en)
ZA (1) ZA926899B (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0565634B1 (en) * 1990-12-14 1999-03-17 Smithkline Beecham Corporation Angiotensin ii receptor blocking compositions
US5484939A (en) * 1993-03-12 1996-01-16 Lonza Ltd. 2-substituted 5-chlorimidazoles
US5721263A (en) * 1993-06-07 1998-02-24 Takeda Chemical Industries, Ltd. Pharmaceutical composition for angiotensin II-mediated diseases
HU218680B (en) * 1997-07-25 2000-10-30 Sanofi-Synthelabo Process for the preparation of 1,3-diaza-spiro(4,4)non-1-en-4-one derivatives and 1-cyano-1-acylamino-cyclopentane intermediates
HU218681B (en) 1997-07-25 2000-10-30 Sanofi-Synthelabo Process for the preparation of 1,3-diaza-spiro(4,4)non-1-en-4-one derivatives and 1-cyano-1-acylamino-cyclopentane intermediates
ES2318899T3 (en) 1998-07-06 2009-05-01 Bristol-Myers Squibb Company BIFENIL SULFONAMIDS AS DUAL ANTAGONISTS OF ANGIOTENSIN AND ENDOTHELINE RECEPTORS.
US6638937B2 (en) 1998-07-06 2003-10-28 Bristol-Myers Squibb Co. Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
AU2004208615C1 (en) 2003-01-31 2010-05-13 Daiichi Sankyo Company, Limited Medicine for prevention of and treatment for arteriosclerosis and hypertension
EP1750862B1 (en) 2004-06-04 2011-01-05 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition containing irbesartan
AU2006238933B2 (en) * 2005-04-28 2011-12-01 Pfizer Limited Amino acid derivatives
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
ES2393885T7 (en) 2007-06-04 2014-01-30 Synergy Pharmaceuticals Inc. Guanylate cyclase agonists useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
ES2522968T3 (en) 2008-06-04 2014-11-19 Synergy Pharmaceuticals Inc. Guanylate cyclase agonists useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
AU2009270833B2 (en) 2008-07-16 2015-02-19 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
CA2905435A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
JP2016514671A (en) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド Guanylate cyclase agonists and uses thereof
US10011637B2 (en) 2013-06-05 2018-07-03 Synergy Pharmaceuticals, Inc. Ultra-pure agonists of guanylate cyclase C, method of making and using same

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH539640A (en) 1970-05-29 1973-07-31 Agripat Sa Herbicidal triazines-2-substd-4-amino-6-(1'-cyclopropyl-1'-cyano - -alkyl-amino)-s-triazines
US4017510A (en) 1975-11-12 1977-04-12 American Cyanamid Company Imidazoisoindolediones and the use thereof as herbicidal agents
DE3545597A1 (en) * 1985-12-21 1987-07-02 Celamerck Gmbh & Co Kg NEW HERBICIDE EFFECTIVE IMIDAZOLINONES
EP0303863A3 (en) * 1987-08-17 1991-10-23 American Cyanamid Company Benzenesulfonyl carboxamide compounds, intermediate compounds and methods of preparation thereof and use of said compounds and intermediate compounds as herbicidal agents
US4880804A (en) * 1988-01-07 1989-11-14 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking benzimidazoles
CA2020073A1 (en) * 1989-07-03 1991-01-04 Eric E. Allen Substituted quinazolinones as angiotensin ii antagonists
EP0412594B1 (en) * 1989-07-28 1996-01-03 Merck & Co. Inc. Substituted triazolinones, triazolinethiones, and triazolinimines as angiotensin II antagonists
IL99372A0 (en) * 1990-09-10 1992-08-18 Ciba Geigy Ag Azacyclic compounds
JP2004247578A (en) 2003-02-14 2004-09-02 Kawasaki Microelectronics Kk Semiconductor device and its manufacturing method

Also Published As

Publication number Publication date
FR2681067B1 (en) 1993-12-17
IL103116A (en) 1998-04-05
LTIP119A (en) 1994-07-15
NO180678C (en) 1997-05-28
RU2107062C1 (en) 1998-03-20
FR2681067A1 (en) 1993-03-12
JPH05213894A (en) 1993-08-24
KR930006008A (en) 1993-04-20
ZA926899B (en) 1993-03-16
LV10255A (en) 1994-10-20
NO923509L (en) 1993-03-11
LT3148B (en) 1995-01-31
NO180678B (en) 1997-02-17
PL171524B1 (en) 1997-05-30
AU2286892A (en) 1993-03-11
CA2077967A1 (en) 1993-03-11
HUT63616A (en) 1993-09-28
IL103116A0 (en) 1993-02-21
LV10255B (en) 1995-04-20
NZ244258A (en) 1996-10-28
MX9205155A (en) 1993-03-01
AU661017B2 (en) 1995-07-13
CZ275992A3 (en) 1993-03-17
TW218871B (en) 1994-01-11
EP0532410A1 (en) 1993-03-17
NO923509D0 (en) 1992-09-09
HU9202889D0 (en) 1992-11-30
PL295874A1 (en) 1993-04-19

Similar Documents

Publication Publication Date Title
MY108089A (en) N-substituted heterocyclic derivatives,their preparation and the pharmaceutical composition in which they are present.
CA2057913A1 (en) N-substituted heterocyclic derivatives, their preparation and the pharmaceutical compositions in which they are present
FR2673427B1 (en) N-SUBSTITUTED DIAZOTATED HETEROCYCLIC DERIVATIVES BY A BIPHENYLMETHYL GROUP, THEIR PREPARATION, THE PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME.
MY110517A (en) Indoline derivatives carrying an amide functional group their preparation and the pharmaceutical compositions in which they are present.
HUP0400887A2 (en) Glycopeptide derivatives and pharmaceutical compositions containing the same
TW200617004A (en) Novel heterocycle-substituted cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
CA2168751A1 (en) Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of disease states at risk for progressing to noninsulin-dependent diabetes mellitus
IL124461A (en) Angiogenesis inhibiting 3-(1,2,4-thiadiazol-5-yl)piperazine pyridazine derivatives their preparation and pharmaceutical compositions containing them
DK0590919T3 (en) Therapeutic agents for Parkinson's disease
BR9610474A (en) Phenyloxazolidinones having a c-c bond to 4-8 membered heterocyclic rings
TW200613297A (en) Pyrazole derivatives
CA2522024A1 (en) Cgrp receptor antagonists
KR900004693A (en) Pyridine Compounds and Pharmaceutical Uses thereof
PE20010931A1 (en) OXAZOLIDINONES THAT HAVE THE FUNCTION OF A SULFOXIMINE
ES2112386T3 (en) THERAPEUTIC AGENTS FOR USE IN THE TREATMENT OF PARKINSON'S DISEASE.
ES476658A1 (en) 4-Amino-3-sulfonamido pyridine derivatives.
ES474215A1 (en) Imidazolylethylene-oxyalkyloxy derivatives and their thio analogues, methods for their preparation and pharmaceutical compositions containing them.
MX9306227A (en) NEW DERIVATIVES OF TAXANE, PROCEDURE FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM.
NZ318515A (en) Cyclodepsipeptide PF1022 derivatives and compositions thereof
HUP9802995A2 (en) Substituted sulphonylamino (thio)carbonyl derivatives, intermediates, thereof herbicide compositions containing these compounds as active ingredients, process for the preparation and use of the compounds and compositions
MY122147A (en) Water soluble azoles as broad-spectrum antifungals
NZ314406A (en) Treatment or prophylaxis of pancreatitis with a medicament containing an insulin sensitiser including oxazoles and thiazoles
KR890016017A (en) Substituted 1- (1H-imidazol-4-yl) alkyl-benzamide
HUP9700955A2 (en) Substituted 2-naphtoylguanidine derivatives, their production, and pharmaceutical compositions containing them
TW333532B (en) Benzopyrans